In contrast, treatment with increasing concentrations of TNF-α significantly decreased benzamil-sensitive Isc in HBECs starting at concentrations of ≥ 0.05 ng/mL (Fig 1E) which was similar to plasma levels observed in patients with acute lung injury, severe COPD or pneumonia [37–41]. Here, TNF is linked to chronic obstructive pulmonary disease.